+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 57 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, pharmacokinetics, and immune response of ABBV-243, a drug given by intravenous IV or subcutaneous SC injection, in healthy adult volunteers. This Phase 1 trial includes two parts Part 1 tests single ascending doses of ABBV-243 or placebo in healthy adults, and Part 2 evaluates a single IV dose in healthy Asian adults. The study aims to understand how ABBV-243 behaves in the body and its safety profile. Participants will receive either a single IV or SC dose of ABBV-243 or a matching placebo on Day 1. Different groups will get varying doses to assess the effects and how the drug is processed. Specific groups include Han Chinese and Japanese adults who will receive a single IV dose or placebo. The study uses a randomized, double-blind design to compare ABBV-243 against placebo. During the study, participants will attend multiple visits at a hospital or clinic for medical assessments, blood tests, and questionnaires to monitor side effects and drug levels. The main outcomes measured include the number of adverse events, maximum drug concentration in blood, time to reach this concentration, overall drug exposure over time, drug elimination rate, half-life, and the presence of antibodies against ABBV-243. Participants will be followed for safety and drug effects up to Day 204 after dosing.

Age: 18Years - 60YearsAll GendersPhase 1
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying ABBV-7828 to assess its safety, how well it is tolerated, how it behaves in the body, and how food intake affects it in healthy adults. This Phase 1 study involves healthy participants aged 18 to 65 years with a body mass index between 18.0 and 32.0 kgm2. The study is randomized and double-blinded, and it compares ABBV-7828 to a placebo. Participants will receive single oral doses of ABBV-7828 or placebo. The study includes two periods where participants receive ABBV-7828 either while fasting or after a high-fat, high-calorie meal to evaluate the effect of food on the drugs pharmacokinetics. The dosing is done sequentially with some participants receiving ABBV-7828 first in fasting conditions followed by fed conditions, and others in the reverse order. Participants will be monitored for adverse events for up to about 38 days and have blood tests to measure drug levels and how the body processes ABBV-7828 over approximately 10 days. Assessments include safety evaluations such as vital signs, ECG, and laboratory tests. The overall study participation duration depends on these follow-up periods, with close monitoring to understand the drugs behavior and safety profile.

Age: 18Years - 65YearsAll GendersPhase 1
1 location
P

Actively Recruiting

Researchers are evaluating ABBV-295, a drug administered by subcutaneous injections, in adults with obesity to assess its safety, effects on body weight, and how the body processes the drug. This Phase 1b study focuses on monitoring adverse events and pharmacokinetics in participants with a body mass index between 30.0 and 45.0 kgm2, including those with stable weight-related health conditions. The study is sponsored by AbbVie and aims to better understand ABBV-295s impact in this population. Participants will be randomly assigned to receive either ABBV-295 or a matching placebo through subcutaneous injections for a treatment period lasting 13 to 20 weeks, depending on their assigned group. Several groups are involved, with some receiving 13 weeks of treatment and others up to 20 weeks. The study is triple-blinded, meaning neither participants nor researchers know who receives the drug or placebo during the trial. Throughout the study, participants will be regularly monitored for adverse events, vital signs, electrocardiogram changes, and clinical laboratory test results for up to approximately 194 days. Researchers will also measure various pharmacokinetic parameters of ABBV-295, including plasma concentration levels and antibody development. Body weight changes from baseline will be tracked as a key outcome. The trial includes ongoing safety assessments and a follow-up period to observe lasting effects.

Age: 18Years - 65YearsAll GendersPhase 1
2 locations
E

Actively Recruiting

Researchers are studying how the drug ABBV-932 behaves in the body and its side effects when taken alone and together with another drug called Itraconazole in adults with bipolar disorder. The study is a Phase 1 trial focused on understanding basic science aspects of these medications in this population. Participants will first receive oral ABBV-932 alone in the first period. In the second period, they will take ABBV-932 combined with oral Itraconazole. The study aims to observe how the body processes these drugs alone and in combination. During the study, researchers will monitor participants for adverse events and measure various drug levels in the blood, including maximum concentration, time to maximum concentration, elimination rate, half-life, and area under the curve over approximately 29 days. Safety monitoring will continue for up to about 61 days. Participants will undergo medical exams, vital sign checks, lab tests, ECGs, and psychiatric assessments throughout the study.

Age: 18Years - 65YearsAll GendersPhase 1
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying ABBV-313 in healthy adult volunteers to understand its safety, tolerability, how the body processes it, and immune response. This research is a Phase 1 trial focusing on both single and multiple doses of ABBV-313, a drug given by injection or infusion. The study is placebo-controlled and randomized to compare effects accurately. Participants will be assigned to one of several groups, receiving either ABBV-313 or a placebo through single or multiple doses, delivered by injection or infusion. These treatments are administered under controlled conditions to assess different dosing schedules and their impact on the body. Throughout the study, participants will be monitored for adverse events, and blood samples will be taken to measure drug levels and pharmacokinetics up to approximately 329 days. This includes monitoring how quickly and how much ABBV-313 appears in the bloodstream and how long it stays active. Safety and immune responses will be carefully followed during this time to evaluate the treatments effects.

Age: 18Years - 55YearsAll GendersPhase 1
2 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating how the drug emraclidine moves through the body and its safety in healthy elderly adults aged 65 to 85 years. This Phase 1, randomized, placebo-controlled study aims to understand the drugs pharmacokinetics, tolerability, and any adverse events in this population. The trial is sponsored by AbbVie and focuses on basic science to gather important information about the drugs effects. Participants will receive oral doses of either emraclidine or a placebo for either 10 days or 17 days, depending on their assigned group. The study uses a sequential design with multiple groups receiving ascending oral doses to assess safety and how the drug is processed in the body. The intervention involves taking oral tablets while the research team monitors participants closely. During the study, participants will undergo various assessments including vital sign measurements, electrocardiograms ECGs, physical examinations, and laboratory tests. Researchers will track changes in safety scales such as the Columbia-Suicide Severity Rating Scale and movement disorder rating scales up to approximately 20 days. Blood samples will be collected to measure drug concentration and metabolism. The total observation period for adverse events may extend up to about 50 days, ensuring thorough safety monitoring.

Age: 65Years - 85YearsAll GendersPhase 1
5 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating ABBV-859 in healthy adult volunteers to study its safety, tolerability, how it moves through the body pharmacokinetics, and immune response after single increasing doses. This is a Phase 1 clinical trial aimed at understanding these factors in adults aged 18 to 65 who are generally healthy. Participants receive a single dose of ABBV-859 or a matching placebo by oral tablet or intravenous infusion on Study Day 1. The doses increase sequentially across different groups to assess the effects of different dose levels. This study uses a randomized and double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will be monitored up to 99 days for side effects, drug levels in the blood, and immune reactions. Assessments include physical exams, vital signs, blood tests, ECGs, and tracking of any adverse events. The study also collects measurements like maximum drug concentration, clearance, and antibody development to understand the drugs behavior and safety profile over time.

Age: 18Years - 65YearsAll GendersPhase 1
2 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
C

Actively Recruiting

Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.

Age: 35Years - 50YearsFEMALEPhase Not Applicable
574 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying ABBV-1451 in healthy adult volunteers to understand how the drug moves through the body pharmacokinetics, the immune response it may trigger immunogenicity, and its safety and tolerability. This early phase 1 trial includes healthy participants, including specific groups of Japanese and Han Chinese adults, to gather important initial data about ABBV-1451. Participants will receive single ascending doses of ABBV-1451 through injections or infusions, with doses increasing stepwise until reaching one of several defined dose levels or a placebo. The study includes multiple groups, some receiving ABBV-1451 while others receive placebo, with special groups for Japanese and Han Chinese participants receiving a single dose at a certain level. During the study, participants will be closely monitored for side effects and drug levels in their blood up to about 211 days. Assessments include medical exams, vital signs, laboratory tests, ECGs, and tracking of any adverse events. This comprehensive monitoring helps researchers measure how the drug behaves and its safety profile over time in healthy adults.

Age: 18Years - 60YearsAll GendersPhase 1
1 location

1-10 of 57

1